Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition

BRAF inhibitors are insufficient monotherapies for BRAF-mutated cancer; therefore, we investigated which inhibitory pathway would yield the most effective therapeutic approach when targeted in combination with BRAF inhibition. The oncogenic BRAF inhibitor, PLX4720, increased basal autophagic flux in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeom, Hojin, Hwang, Sung-Hee, Han, Byeal-I, Lee, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255135/
https://www.ncbi.nlm.nih.gov/pubmed/33551379
http://dx.doi.org/10.4062/biomolther.2020.203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255135/
https://www.ncbi.nlm.nih.gov/pubmed/33551379
http://dx.doi.org/10.4062/biomolther.2020.203

Ejemplares similares